Amyl Therapeutics Company
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Founded Date:
2020-11-01
Last Funding Date:
2023-11-07
Industry:
Quantum Biology
Total Funding:
34393625
Headquarters:
Liège,Liege,Belgium,Europe
Funding Status:
private
Super Industry:
Quantum Science Applications
Funding Stage:
Early Stage Venture
Funding Total Value:
29700000
Last Funding Total Usd:
6524957
Last Funding Total Currency:
EUR
Last Funding Total Value:
6100000
Founders:
Florent Gros,Pierre Vandepapelière